Adenomatous-Dominant Benign Prostatic Hyperplasia (AdBPH) as a Predictor for Clinical Success Following Prostate...

Area of Science:

• Urology
• Interventional Radiology
• Medical Imaging

Background:

• Benign prostatic hyperplasia (BPH) affects a significant number of aging men.
• Adenomatous-dominant BPH (AdBPH) presents unique challenges in BPH management.
• Prostate artery embolization (PAE) is an emerging minimally invasive treatment for BPH.

Purpose of the Study:

• To evaluate the clinical impact of PAE in patients with AdBPH.
• To compare PAE outcomes in AdBPH patients versus non-AdBPH patients.
• To identify AdBPH as a potential predictor of PAE success.

Main Methods:

• Retrospective analysis of 12 AdBPH patients from the STREAM trial.
• Age-matched comparison with non-AdBPH patients from the STREAM cohort.
• Multi-parametric MRI (MP-MRI) for AdBPH definition and follow-up.
• Assessment of International Prostate Symptom Score (IPSS), IIEF, and quality of life (QOL) at various time points.

Main Results:

• PAE demonstrated high technical success (96%) in the AdBPH cohort.
• Significant prostate volume reduction in AdBPH patients (34%) compared to non-AdBPH (22%).
• AdBPH patients showed significant improvements in IPSS (8 vs. 13) and QOL scores post-PAE.
• No observed deterioration in sexual function for either group.

Conclusions:

• Adenomatous-dominant BPH is identified as a predictor of clinical success following PAE.
• PAE offers significant symptomatic relief and improved quality of life for AdBPH patients.
• PAE is a safe and effective treatment option for AdBPH, preserving sexual function.